Ayako Yano
Overview
Explore the profile of Ayako Yano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
81
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Doi K, Nito F, Yano A, Nagura R, Kawano S
J Vis Exp
. 2018 Sep;
(139).
PMID: 30247473
To drive electrohydrodynamic (EHD) flows in aqueous solutions, the separation of cation and anion transport pathways is essential because a directed electric body force has to be induced by ionic...
2.
Doi K, Yano A, Kawano S
J Phys Chem B
. 2014 Nov;
119(1):228-37.
PMID: 25412032
In recent years, the control of ionic currents has come to be recognized as one of the most important issues related to the efficient transport of single molecules and microparticles...
3.
Satoh K, Tanaka M, Yano A, Ying J, Kakuma T
World J Surg
. 2012 Dec;
37(3):516-24.
PMID: 23229849
Background: The St. Gallen consensus provides treatment recommendations for breast cancer based on prognostic factors. Although many patients' prognostic patterns are not easily matched with the prognostic patterns listed in...
4.
Yamaguchi R, Tanaka M, Yano A, Tse G, Yamaguchi M, Koura K, et al.
Hum Pathol
. 2012 Apr;
43(10):1688-94.
PMID: 22516244
Neoadjuvant chemotherapy or preoperative systemic therapy is increasingly considered for patients with operable breast cancer. Patients with breast cancer were examined for pathologic factors predictive of response to neoadjuvant chemotherapy,...
5.
Yano Y, Hoshide S, Ishikawa J, Noguchi C, Tukui D, Takanori H, et al.
Am J Hypertens
. 2007 May;
20(5):565-72.
PMID: 17485023
Background: A dual angiotensin type 1 receptor blocker (ARB)/peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist telmisartan may be more useful for microalbuminuria reduction than ARBs with no PPARgamma agonistic action. We investigated...